China Pharma Reports Slightly Higher Q2 Profits, Expects To Launch Generic Version Of AstraZeneca's Crestor In 2010
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China Pharma Holdings, a generic drug provider in China, reported that its net income inched up by 6.2 percent to $4.3 million in the second quarter of 2009 compared with the same period of 2008
You may also be interested in...
China Pharma Holdings Sees Increased Revenue From Sales Of Generic Version Of Bayer’s Aleve-D
SHANGHAI - China Pharma Holdings reported a 39 percent increase in net income to $17.8 million in 2008 due to a 76.6 percent increase in sales of its leading OTC cold and flu product PuSen OK (naprooxen and pseudophedrine), the only generic version in China of Bayer's Aleve-D
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).